Skip to main navigation
logo
  • Overview
  • Corporate
    • Corporate Profile
    • Management
    • Board of Directors
    • Key Advisors
    • Corporate Governance
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Quarterly Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • IR Contacts

News & Events

News Releases

News Releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
2023.05.04
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
2023.04.28
Adagene Announces Updates to its Board of Directors
2023.04.18
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
2023.03.28
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
2023.03.14
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Displaying 1 - 5 of 62

Shareholder Tools

  • © 2023 Adagene Inc.

Footer Bottom

  • Home
  • Privacy
  • Terms of Use
  • Contact
  • Site Credits
  • LinkedIn